Clinical Trial Update: Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC

View source ↗

Summary

A completed clinical trial comparing lenvatinib versus bevacizumab plus immune checkpoint inhibitors and HAIC in unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Immune checkpoint inhibitors (unspecified)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Lenvatinib | Status: COMPLETED